On August 7, WUXI XDC rose 3.07% in regular trading, trading at HKD 57.2/share, with turnover of HKD 36.63 million. The rally was driven by rising expectations ahead of the company's interim results review scheduled for August 24, combined with broad-based CXO sector strength.

On the news front, CLSA previously raised its target price on WUXI XDC to HKD 82.6, maintaining an Outperform rating, forecasting revenue and adjusted net profit growth to exceed guidance. Daiwa initiated coverage with a Buy rating and HKD 78 target price, naming the company a top pick in China's CXO industry, citing its 24% global ADC outsourcing market share and full-chain CRDMO capabilities.

Sector linkage effects remained pronounced on the same day, with Pharmaron up 6.12%, Wuxi AppTec up 3.9%, and Wuxi Bio up 3.72%. Global biotech financing recovery and robust ADC R&D investment continued to drive pre-positioning by institutional capital.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)